文献速递前列腺癌

B7-H3作为晚期前列腺癌的治疗靶点

B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
PubMed 文献 · Eur Urol · 2022-09-13

本研究对98例临床注释的前列腺癌活检组织进行免疫组化和二代测序,其中72例有配对激素敏感期活检,分析B7-H3表达与基因组学关联,并在人源前列腺癌模型(细胞系、类器官、移植瘤)中评估抗B7-H3抗体偶联药物DS-7300a的抗肿瘤活性。

要点

  • B7-H3是去势抵抗性前列腺癌中高表达的免疫调节基因之一,93%的CRPC表达B7-H3。
  • 在进展为CRPC的患者中,97%在激素敏感期诊断时即表达B7-H3,HSPC向CRPC进展过程中阳性转阴性或反之少见。
  • DS-7300a在表达B7-H3的人前列腺癌模型(细胞系、类器官、腺癌和神经内分泌组织学移植瘤)中具有抗肿瘤活性。

核心结论

  • B7-H3在CRPC中较正常组织和其他B7家族成员频繁过表达,提示其是这些疾病高度相关的治疗靶点。
  • 驱动不同基因组亚群间B7-H3表达差异的机制值得研究,以理解B7-H3在癌症生长中的作用及用于B7-H3靶向治疗的临床开发。

研究设计与样本

  • 对98例临床注释的CRPC活检组织进行免疫组化和二代测序,其中72例患者同时有HSPC活检用于分析。
  • 分析两个CRPC转录组和外显子组数据集及前列腺癌单细胞RNA测序数据集。
  • 前列腺癌类器官由人CRPC活检来源的PDX衍生而来(PDX来源类器官PDX-Os)。
  • 在770个免疫相关基因panel中评估B7-H3 mRNA表达,比较同一患者HSPC与CRPC活检的B7-H3蛋白表达,确定与前列腺癌基因组改变的关联。
  • 在人前列腺癌细胞系、不同组织学/B7-H3表达/基因组学的类器官(PDX-Os)和移植瘤(PDXs)中评估DS-7300a(拓扑异构酶-1抑制剂载荷的抗B7-H3抗体偶联药物)的抗肿瘤活性。

主要发现

  • B7-H3是CRPC中表达最高的免疫调节基因之一。
  • 大多数CRPC(93%)表达B7-H3,在进展为CRPC的患者中,B7-H3在HSPC诊断时经常表达(97%)。
  • 从HSPC向CRPC进展过程中,B7-H3阳性转阴性或阴性转阳性不常见。
  • 具有神经内分泌特征的CRPC较腺癌更可能为B7-H3阴性(28%)。
  • B7-H3在DNA修复基因(ATM和BRCA2)缺陷的肿瘤中过表达,并与ERG表达、雄激素受体(AR)表达及AR活性特征相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: B7-H3 is a cell surface immunomodulatory glycoprotein overexpressed in prostate cancers (PCs). Understanding its longitudinal expression at emergence of castration resistance and association with tumour genomics are critical to the development of and patient selection for B7-H3 targeted therapies. OBJECTIVE: To characterise B7-H3 expression in same-patient hormone-sensitive (HSPC) and castration-resistant (CRPC) PC biopsies, associating this with PC genomics, and to evaluate the antitumour activity of an anti-B7-H3 antibody-drug conjugate (ADC) in human CRPC in vitro and in vivo. DESIGN, SETTING, AND PARTICIPANTS: We performed immunohistochemistry and next-generation sequencing on a cohort of 98 clinically annotated CRPC biopsies, including 72 patients who also had HSPC biopsies for analyses. We analysed two CRPC transcriptome and exome datasets, and PC scRNASeq datasets. PC organoids (patient-derived xenograft [PDX]-derived organoids [PDX-Os]) were derived from PDXs generated from human CRPC biopsies. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We evaluated B7-H3 mRNA expression in relation to a panel of 770 immune-related genes, compared B7-H3 protein expression between same-patient HSPC and CRPC biopsies, determined associations with PC genomic alterations, and evaluated the antitumour activity of DS-7300a, a topoisomerase-1 inhibitor payload anti-B7-H3 ADC, in human PC cell lines, organoids (PDX-Os), and xenografts (PDXs) of different histologies, B7-H3 expressions, and genomics. RESULTS AND LIMITATIONS: B7-H3 was among the most highly expressed immunomodulatory genes in CRPCs. Most CRPCs (93%) expressed B7-H3, and in patients who developed CRPC, B7-H3 expression was frequently expressed at the time of HSPC diagnosis (97%). Conversion from B7-H3 positive to negative, or vice versa, during progression from HSPC to CRPC was uncommon. CRPC with neuroendocrine features were more likely to be B7-H3 negative (28%) than adenocarcinomas. B7-H3 is overexpressed in tumours with defective DNA repair gene (ATM and BRCA2) alterations and is associated with ERG expression, androgen receptor (AR) expression, and AR activity signature. DS7300a had antitumour activity against B7-H3 expressing human PC models including cell lines, PDX-Os, and PDXs of adenocarcinoma and neuroendocrine histology. CONCLUSIONS: The frequent overexpression of B7-H3 in CRPC compared with normal tissue and other B7 family members implicates it as a highly relevant therapeutic target in these diseases. Mechanisms driving differences in B7-H3 expression across genomic subsets warrant investigation for understanding the role of B7-H3 in cancer growth and for the clinical development of B7-H3 targeted therapies. PATIENT SUMMARY: B7-H3, a protein expressed on the surface of the most lethal prostate cancers, in particular those with specific mutations, can be targeted using drugs that bind B7-H3. These findings are relevant for the development of such drugs and for deciding which patients to treat with these new drugs.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Guo C, Figueiredo I, Gurel B, et al. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. Eur Urol. 2022. PMID: 36114082. doi:10.1016/j.eururo.2022.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。